妇科肿瘤早期与晚期临床试验的完成、报告及少数族裔入组趋势
该研究基于ClinicalTrials.gov 2007至2020年注册的妇科肿瘤试验,比较早期与晚期试验的完成率、报告率及少数族裔入组情况。结果显示早期试验发表率高于晚期试验,晚期试验更常报告种族数据,但早期试验更可能入组少数族裔。
要点
- 早期妇科肿瘤试验发表率18.4%,高于晚期试验的8.6%(p<0.001)。
- 晚期试验报告种族数据的比例64.4%,高于早期试验的33.7%(p<0.0001)。
- 报告种族数据的试验中,晚期试验白人患者占85.7%,早期试验占72.0%(p<0.001)。
核心结论
- 妇科肿瘤早期试验比晚期试验更可能达到发表。
- 晚期试验更常报告种族数据,但早期试验更可能入组少数族裔。
研究设计与样本
- 研究比较了2007至2020年在ClinicalTrials.gov注册的妇科肿瘤早期与晚期试验。
- 共识别223,690项试验,其中2146项(0.9%)聚焦妇科肿瘤。
主要发现
- 妇科肿瘤试验中卵巢癌占50.8%(n=1092),宫颈癌占16.3%(n=350),子宫癌占15.6%(n=334)。
- 仅22.1%(n=474)的试验报告结果或发表。
- 早期试验发表率18.4%,晚期试验8.6%(p<0.001)。
- 在美国发表的试验中,早期试验占79.0%(199/252),晚期试验占17.9%(45/252)。
- 早期试验报告种族数据的比例为33.7%(n=67),晚期试验为64.4%(n=29,p<0.0001)。
临床怎么用
- 需关注妇科肿瘤试验整体发表率低及晚期试验少数族裔入组不足的问题。
- 应进一步研究以确定低发表率和少数族裔相对入组不足的原因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare early- vs. late-phase gynecologic oncology trials with respect to rates of trial completion and enrollment of racial and ethnic minority groups (REMGs). METHODS: Gynecologic oncology studies registered on ClinicalTrials.gov between 2007 and 2020 were identified and compared between early- and late- phase trials. Reporting and publication rates were compared. Trials with published results were analyzed based on reporting of race/ethnicity in relation to disease site and trial characteristics. RESULTS: Of 223,690 trials identified, 2146 (0.9%) were focused on gynecologic oncology. Most gynecologic oncology trials investigated ovarian cancer (n = 1092, 50.8%), followed by cervical cancer (n = 350, 16.3%), and uterine cancer (n = 334, 15.6%). Only 22.1% (n = 474) of trials either reported results or led to publication. Early-phase trials were more likely to be published than late-phase trials (18.4% vs. 8.6%, p < 0.001). Among US-based trials which published (n = 252), 199 were early-phase (79.0%; phase I, phase I/II, or phase II), and 45 late-phase (17.9%; phase II/III, III or phase IV). 33.7% of early-phase trials (n = 67) reported race/ethnicity data compared to 64.4% of late-phase trials (n = 29, p < 0.0001). Of those trials which reported race/ethnicity, more patients identified as White (85.7%) in late-phase trials as compared to early-phase trials (72.0%, p < 0.001). CONCLUSION: In clinical trials in gynecologic oncology, early-phase trials were more likely to reach publication than late-phase trials. While late-phase trials were more likely to report race/ethnicity data compared to early-phase trials, early-phase trials were more likely to enroll REMGs. Further research must be conducted to determine reasons for the overall low publication rates of gynecologic oncology trials and relative under-enrollment of REMGs in late-phase trials, in order to work towards reducing these inequities in the future.
引用
- Richardson MT, Barry D, Steinberg JR, et al. Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groups. Gynecol Oncol. 2026. PMID: 42628252. doi:10.1016/j.ygyno.2026.08.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。